ARTICLE | Clinical News
EB-1020 SR: Interim Phase IIa data
February 10, 2014 8:00 AM UTC
Interim data from the single-blind, U.S. Phase IIa EB-1020-ADHD-201 trial in 40 adult male ADHD patients showed that 150-250 mg doses of twice-daily EB-1020 SR significantly improved ADHD-RS-IV score ...